THINK Surgical’s Next-Generation Robot System 1st Knee Replacement Procedure Performed at Hackensack University Medical Center

THINK Surgical's TSolution One® Robot Features Unmatched Choice of Implant Options

THINK Surgical’s Next-Generation Robot System: Hackensack University Medical Center, a national leader in orthopedic care and robotic surgery, recently completed the first total knee replacement on the East Coast using the newest generation of the TSolution One robot from THINK Surgical. The system, manufactured by the Fremont, CA – based company features a true, active robot which supports a choice of knee implants from multiple manufacturers in its open implant library.

The procedure was performed by Yair D. Kissin, M.D.*, vice chair, Department of Orthopedics at Hackensack Meridian Health Hackensack University Medical Center. Dr. Kissin praised the system saying, “I am pleased to be able to offer this state-of-the-art technology to my patients. The robot makes incredibly accurate cuts which is important to ensure proper fit of the implant and avoid loosening that can occur with poor cuts.  In addition, the open platform allows me unrivaled choices to personalize the procedure for each patient.”

“We are thrilled to work with Dr. Kissin and the orthopedics team at Hackensack University Medical Center,” said Stuart Simpson, CEO of THINK Surgical, Inc. “Our active robot system helps surgeons perform total knee replacement procedures with unrivaled accuracy. Just as important, the system incorporates an open implant library, which allows surgeons to choose the implant best suited for their patients from an array of companies.”

“Hackensack University Medical Center is proud to be at the forefront of robotic technology and orthopedic surgery,” added Mark D. Sparta, FACHE, president and chief hospital executive, Hackensack University Medical Center and executive vice president of Population Health, Hackensack Meridian Health.” The addition of this active robot delivers the type of leading-edge care we strive to provide for our patients.”

The TSolution One® Total Knee Application combines two exclusive innovations to advance total joint replacement surgery. The system consists of TPLAN®, a 3D pre-surgical planning workstation and TCAT®, an active robot. The pre-surgical planning allows the surgeon to design and prepare the patient’s unique joint replacement in a virtual environment plan leveraging a choice of implant options. During the joint replacement surgery, the surgeon implements the patient’s pre-planned procedure using the active robot, which prepares the joint according to the surgeon’s plan delivering precise placement of implants.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy